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Buenos Aires, ArgentinaABSTRACT Protein aggregation is linked to more than 30 human pathologies, including Alzheimer’s and Parkinson’s
diseases. Since small oligomers that form at the beginning of the fibrillation process probably are the most toxic elements,
therapeutic strategies involving fibril fragmentation could be detrimental. An alternative approach, named kinetic inhibition,
aims to prevent fibril formation by using small ligands that stabilize the parent protein. The factors that govern fibrillation lag times
during kinetic inhibition are largely unknown, notwithstanding their importance for designing effective long-term therapies. Inhib-
itor-bound species are not likely to be incorporated into the core of mature fibrils, although their presence could alter the kinetics
of the fibrillation process. For instance, inhibitor-bound species may act as capping elements that impair the nucleation process
and/or fibril growth. Here, we address this issue by studying the effect of two natural inhibitors on the fibrillation behavior of
lysozyme at neutral pH. We analyzed a set of 79 fibrillation curves obtained in lysozyme alone and a set of 37 obtained in
the presence of inhibitors. We calculated the concentrations of the relevant species at the beginning of the curves using the
inhibitor-binding constants measured under the same experimental conditions. We found that inhibitor-bound protein species
do not affect fibrillation onset times, which are mainly determined by the concentration of unbound protein species present in
equilibrium. In this system, knowledge of the fibrillation kinetics and inhibitor affinities suffices to predict the effect of kinetic
inhibitors on fibrillation lag times. In addition, we developed a new methodology to better estimate fibrillation lag times from
experimental curves.INTRODUCTIONProtein aggregation is associated with more than 30 human
pathologies, including Alzheimer’s disease, Parkinson’s dis-
ease, and type II diabetes (1). Since the crucial interactions
that stabilize the cross-b-sheet structure of the fibrils found
in such diseases are provided by the peptide backbone, the
potential to form amyloid structures is an intrinsic property
of many naturally expressed proteins. In this sense, several
proteins not linked to aggregation pathologies can form am-
yloid fibers under suitable conditions, which usually involve
a perturbation of the native structure (2–4). Moreover,
mutations that reduce the conformational stability of pro-
teins can also favor their conversion into structures that
are able to form fibrils. For instance, mutations that destabi-
lize the tetrameric assembly of transthyretin (5) or the
tertiary structure of lysozyme (6) are linked to the early-
onset variants of the associated pathologies. Several strate-
gies have been proposed to treat these diseases (7). The
efficacy of any treatment will depend on the molecular
nature of the toxic species and their mechanism of toxicity.Submitted January 10, 2014, and accepted for publication June 18, 2014.
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mers that form during the initial stages of fibrillation as
the most toxic species (8–11). In this scenario, strategies
aimed at breaking mature fibrils could be detrimental
because they could increment the concentration of these pu-
tatively more toxic oligomers. An alternative approach is to
reduce the concentration of the small oligomeric forms. This
can be achieved either by accelerating their conversion into
mature and less toxic fibrils (12) or by inhibiting their
formation from the parent soluble protein. For instance, it
has been shown that small compounds such as epigallocate-
chin-3-gallate, an abundant compound in green tea leaves,
can favor the formation of innocuous off-pathway oligo-
meric species (13,14). An alternative approach, termed
kinetic inhibition, involves stabilizing the native protein
conformation by small ligands to inhibit its initial conver-
sion into oligomers (15). The recent approval of tafamidis
to treat the systemic amyloidosis caused by transthyretin
illustrates the therapeutic potential of this approach (16).
This drug stabilizes the native tetrameric form of the pro-
tein, thus inhibiting its dissociation into monomers, the
rate-limiting step of this fibrogenic pathway. In some cases,
a parallelism between the binding free energy of small
compounds and their efficiency to inhibit fibril formation
has been observed (17). For example, the concentration ofhttp://dx.doi.org/10.1016/j.bpj.2014.06.029
712 Pagano et al.trifluoroethanol that is needed to trigger the fibrillation of
human acylphosphatase increases in the presence of anions
that bind to the protein, displaying a good correlation with
the free energy of stabilization upon binding (18).
Inhibitor-bound protein species are not likely to be incor-
porated into the core ofmature fibrils, although their presence
could affect the kinetics of fibrillation. For example, they
could act as nucleation sites of fibril growth or may function
as capping elements of growing fibrils. In both scenarios,
these species would change the kinetics of fibrillation
because they would no longer be passive bystanders in the
process. In this regard, it has been found that intact, full-
length lysozyme inhibits the fibrillation process of the nicked
protein that takes place under acidic conditions, presumably
by acting as a capping element of the growing protofibrils
(19). Given the promising applications of this strategy, it is
important to determinewhether inhibitor-bound species alter
the kinetics of fibrillation processes. In addition, to forecast
the outcome of long-term therapies, it would be useful to
predict the fibrillation lag times in the presence of kinetic
inhibitors. Here, we address these issues by studying the
fibrillation kinetics of hen lysozyme, one of the most
commonly employed systems in this area of knowledge
(20,21). This protein can readily form cross-b-fibrils under
diverse experimental conditions, and there are several exam-
ples of the effect of small molecules on this process. For
instance, the natural lysozyme inhibitor N,N0,N00-triacetyl-
chitotriose (tri-GlcNAc) has been shown to retard lysozyme
fibrillation in a dose-dependent manner (22). In this work,
we studied the effect of the natural inhibitors N,N0-diacetyl-
chitobiose (di-GlcNAc) and N,N0,N00-triacetylchitotriose on
the kinetics of lysozyme fibrillation. As a result, we were
able to identify the main factors that govern fibrillation lag
times during kinetic inhibition in this system.MATERIALS AND METHODS
Materials
Chicken lysozyme (three times crystallized), thioflavin T (ThioT), guanidi-
nium hydrochloride (Gdn-HCl), di-GlcNAc, and tri-GlcNAc were pur-
chased from Sigma-Aldrich (St. Louis, MO).Lysozyme unfolding studies
For lysozyme unfolding studies, 1 mg/ml lysozyme in 20 mM KH2PO4
(pH 6.3) and the indicated concentrations of Gdn-HCl were incubated for
16 h at 45C. Fluorescence spectra were acquired at the same temperature
in 4 mm path-length fluorescence cells (Starna Cells, Atascadero, CA)
using a JASCO FP-6500 spectrofluorometer endowed with a Peltier-effect
thermostatized cell holder (JASCO International, Tokyo, Japan). The exci-
tation wavelength was 295 nm and spectra were acquired from 300 to
420 nm at 50 nm/min. Bandpass excitation and emission were 3 nm. The
spectra shown are the average of four scans after subtracting the appropriate
blanks. Far-UV circular dichroism (CD) spectra were acquired at 45C in
1 mm cells (Hellma) using a JASCO J-815 spectropolarimeter endowed
with a Peltier-effect thermostatized cell holder. The spectra shown are the
average of four scans at 50 nm/min after subtracting the appropriate blanks.Biophysical Journal 107(3) 711–720A model describing a two-state unfolding transition was fitted to the
measured fluorescence intensity at 354 nm or the CD signal at 220 nm using
the data collected with 0.5–6.5 M Gdn-HCl.Determination of inhibitor dissociation constants
Inhibitor dissociation constants were determined by titrating a lysozyme
solution (10.2 mM) in 20 mMKH2PO4 (pH 6.3) with or without the addition
of 3 M Gdn-HCl. Inhibitor binding was followed from the changes of the
intrinsic fluorescence of lysozyme using a JASCO FP-6500 spectrofluorom-
eter. Titrations were performed by sequentially adding the ligands from a
stock solution made in the same buffer (with or without 3 M Gdn-HCl).
The excitation wavelength was set to 295 nm and the emission spectra were
recorded from 300 to 400 nm. Bandpass excitation and emission were set
to 1 and 5 nm, respectively. Spectra measurements were recorded after an
equilibration time of 15min, when no further changes in the spectra were de-
tected. Each spectrum is the average of four scans. A model considering
ligand binding and protein denaturation equilibria were fitted to the recorded
fluorescence intensity at 319 nm (see SupportingMaterial for further details).Fibril formation experiments
An aliquot of a concentrated solution of lysozyme (30 mg/ml) in 20 mM
KH2PO4 (pH 6.3) was diluted in a 1 1 cm fluorescence cell (Starna Cells)
to reach a final volume of 3 ml and a final concentration of 3 M Gdn-HCl,
20 mM KH2PO4 (pH 6.3). Both solutions were preheated at 45
C. Samples
were stirred with a magnetic bar at 500 rpm and kept at 45C. Fibril forma-
tion was followed by light scattering or by ThioT fluorescence using a
JASCO FP-6500 spectrofluorometer endowed with a thermostatized cell
holder. Light scattering was performed by irradiating and detecting the
scattered light at 360 nm. Bandpass excitation and emission were set to
1 nm. For fluorescence detection, ThioT was added to the initial solution
to reach a final concentration of 20 mM. Excitation and emission wave-
lengths were 440 nm (1 nm bandpass) and 485 nm (5 nm bandpass), respec-
tively. In both experiments, the time response of the detector was set to 8 s
to reduce noise and data points were acquired every 10 s.Determination of curve parameters
The relevant kinetic parameters tlag and t1/2 were extracted by fitting the
following equation to the data (23):
F ¼ Fmax
ð1þ v:ek:ðttmÞÞ1=v
where F is the fluorescence signal, Fmax is the maximum steady-state fluo-
rescence, tm is the point of the maximum elongation rate, and v describes
the asymmetry of the curve. The lag time (tlag) is the time where the tangent
at tm crosses the initial baseline and is given by tm  (1 þ v)/k. In addition,
the growth halftime (t1/2) is given by tm k1 ln((2v 1)/v). Curve fitting
was done with OriginPro 8.6. In addition, we developed a second method to
estimate more accurately the time required for the onset of fibrillation. This
method is a numeric implementation of a variational approach in which a
split derivatable function is fitted to the initial portion of the experimental
curves (up to 5% progression). The split function is composed of a linear
function (F ¼ a þ b  t, for t % t) followed by a quadratic function
(F ¼ a þ b  t þ c  (t  t)2, for t > t). The intersection point between
both functions (t) is used as a variational parameter to generate a set of test
functions, which are individually fitted to the experimental data. Numerical
calculations were performed with an Excel Visual Basic script written ad
hoc. The quadratic error of the fittings for all possible t displays a global
minimum at a particular time (named tlag). This latter parameter accurately
reflects the time when the signal first departs from the initial baseline.
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The kinetic model developed by Knowles et al. (24) was globally fitted to
the lysozyme fibrillation curves measured in the absence of inhibitors. This
model takes into account the size of the growth nuclei (nc) and the kinetics
constants of primary nucleation (kn), polymerization (kþ), and secondary
nucleation (k). The concentration of monomer (M(t)) in the fibers as a
function of time is given by
MðtÞ ¼ mtot:

1 exp Cþek:t þ Cek:t þ knmnc1tot k1

where mtot is the total protein concentration and k ¼ (2 mtot kþ k)1/2. In the
nc1absence of fibrils at the beginning of the incubation, C5 ¼5knmtot =2k.
To connect the concentration of fibers at a given time with the measured
ThioT fluorescence signal, a calibration curve was determined. To this
end, we measured the fluorescence intensity of serial dilutions of a fibril
sample made with 5 mg/ml lysozyme. A sigmoid curve was fitted to these
data. In addition, the detection limit of the assay was estimated by linear
extrapolation of the measured signal for the more diluted samples. Global
fitting of the kinetic models were performed with OriginPro 8.6 with a
script that transforms the concentration of fibers predicted by the kinetic
model into its corresponding fluorescence signal using the calibration
function. For the fitting procedure, these values were then compared with
the experimental measurements.Fibril formation followed by CD spectroscopy
Fibrillation of 1.5 mg/ml lysozyme with or without the addition of 1.5 mM
tri-GlcNAc was followed by light scattering at 360 nm. At the indicated
times, aliquots of 25 ml were diluted with 250 ml of 20 mM KH2PO4,
3 M Gdn-HCl (pH 6.3) at 20C. At this temperature, the fibrillation process
halts without reversion of the aggregated products. Far-UV CD spectra were
acquired immediately at 20C in 1 mm cells (Hellma) using a JASCO J-815
spectropolarimeter. The spectra shown are the average of 10 scans acquired
at 50 nm/min after blank subtraction.Transmission electron microscopy
and atomic force microscopy sample
preparation and imaging
Fibrils that formed with 1.5 mg/ml lysozyme incubated for 10 h with or
without the addition of 1.5 mM tri-GlcNAc were centrifuged at 9300 g
for 5 min and resuspended in H2O. For atomic force microscopy (AFM),
a drop of 20 ml was deposited onto freshly cleaved muscovite mica. After
5 min, the sample was gently washed with 0.5 ml Milli-Q water to remove
molecules that were not firmly attached to the mica and blown dry with
nitrogen. Tapping-mode AFM was performed using a Multimode-AFM
with a Nanoscope IIa-Quadrex controller (Digital Instruments, Veeco
Metrology Group; Santa Barbara, CA) with a J-type piezoelectric scanner.
Images were processed using WSxM3_0Beta12_5 software (Nanotec,
Madrid, Spain) (25). Transmission electron microscopy (TEM) images of
fibrils stained during 50 s with 2% (w/v) uranyl acetate were acquired
with an EM 301 Philips microscope at 60 kV. All images were taken at
the Center of Advanced Microscopy (School of Sciences, University of
Buenos Aires).RESULTS
Lysozyme fibrillation at neutral pH
To understand the mechanism of fibril formation, we first
determined the conditions that were required to drive nativelysozyme to a fibril-prone state. Gdn-HCl-induced unfold-
ing of lysozyme at 45C and pH 6.3 under nonreducing con-
ditions was followed by intrinsic fluorescence (Fig. S1 A)
and far-UV CD (Fig. S1 B). The aim of this experiment
was to characterize the unfolding behavior of lysozyme un-
der these particular conditions, a piece of information that is
not available in the literature. Both techniques revealed a
major transition centered at 3 M Gdn-HCl. In addition,
far-UV CD displayed a minor change at low Gdn-HCl con-
centrations (<0.5 M), probably due to a small readjustment
of the native fold. A two-state unfolding transition model
was fitted to both data sets collected with 0.5–6.5 M Gdn-
HCl (Fig. S1 C). The DGH20 and [Gdn-HCl]50 values calcu-
lated from the fluorescence experiment were 27.9 kJ.mol1
and 2.97 M, respectively. Similar values were obtained
from the CD data (DGH20 ¼ 28.8 kJ.mol1, [Gdn-HCl]50 ¼
3.01 M). This coincidence suggests a two-state unfolding
mechanism without significantly populated intermediates.
This result is at variance with the thermal unfolding of lyso-
zyme at acidic pH (26,27) or in the presence of trifluoroetha-
nol (28), in which molten globule-like intermediates are
populated at equilibrium. On the other hand, the unfolding
curve was performed under equilibrium conditions after a
16 h incubation, and therefore the folding intermediates
found in kinetic experiments were not detected here (29,30).
Lysozyme incubated at intermediate Gdn-HCl concentra-
tions forms amyloid fibrils within a few hours (31). Here, we
employed similar conditions (45C and 3 M Gdn-HCl) to
generate a set of fibrillation curves. ThioT fluorescence
(Fig. 1 C) and light scattering at 360 nm (Fig. S2 A) re-
corded during this process displayed a sigmoid-shaped
curve typical of a nucleation-elongation mechanism. Far-
UV CD spectra revealed the generation of species rich in
b sheet, with an ellipticity minimum at 218 nm (Fig. S2
B). The amyloid nature of the product formed was further
confirmed by AFM (Fig. 1 A) and TEM (Fig. S3, A and B).
We generated a set of 79 lysozyme fibrillation curves
followed by ThioT fluorescence, and normalized their signal
to better compare their shape (Fig. 1 C). The original non-
normalized curves are shown in Fig. S4. The protein con-
centration spanned over 2 orders of magnitude, ranging
from 5 mg/ml (340 mM) to 0.025 mg/ml (1.7 mM). The fluo-
rescence curves were normalized and the kinetic parameters
tlag and t1/2 were calculated as described by Pedersen et al.
(23) (Fig. 1 D).
Even though ThioT may affect the fibrillation process, the
same method was applied for curves generated with and
without inhibitors, and any spurious effect would be ex-
pected to affect both sets of experiments similarly. The alter-
native method, which measures ThioT fluorescence of
an aliquot, usually involves a 20- to 50-fold dilution of the
samples. This procedure impairs the sensitivity of the assay
and seriously overestimates the real lag times of the more
diluted samples. In the protocol employed here, the ThioT
fluorescence signal changes linearly with fibril content atBiophysical Journal 107(3) 711–720
FIGURE 1 Fibril formation by lysozyme. (A and B) AFM image of fibrils
formed with 1.5 mg/ml lysozyme (A) without or (B) with the addition of
1.5 mM tri-GlcNAc. (C) Normalized ThioT fluorescence of 79 fibrillation
curves with lysozyme concentrations ranging from 5 to 0.025 mg/ml. Indi-
vidual conditions were measured in quadruplicate, quintuplicate, or sextu-
plicate. (D) Curve parameters were calculated by fitting a sigmoid function
to the experimental curves. In this case, c0 ¼ 0.15 mg/ml.
714 Pagano et al.low concentration, i.e., at the beginning of the fibrillation
process, and saturates at high fiber concentration. We chose
this approach because we were interested in detecting the
onset times of fibrillation, and therefore our conclusions
are based on this parameter. To find a suitable kinetic model
to describe this system, we had to relate the calculated fibril
concentrations from the models to the experimental signal.
To this end, we performed a calibration curve by measuring
the ThioT fluorescence of serial dilutions of a fibril sample
generated with 5 mg/ml lysozyme (Fig. S5). A nonlinear
response of ThioT fluorescence above 0.5 mg/ml of fibrils
was observed, probably due to inner filter effects. A sigmoid
function fitted well to these data. In addition, a detectionBiophysical Journal 107(3) 711–720limit of 0.47 mM was estimated by linear extrapolation
of the signal measured at low protein concentration
(Fig. S5 B). The sigmoid function was employed to calcu-
late the expected signals for fibril concentrations above
the detection limit; otherwise, a null signal was assumed.
This procedure reproduces the observed lag phase of the
curves, where the concentration of fibrils is below the detec-
tion limit of the assay. It should also be noted that at basic
pH, ThioT may suffer a reversible hydroxylation process
that modifies its spectral features. This modification is negli-
gible under the experimental conditions employed here (32).
Classical nucleation-elongation models state that t1/2 and
the initial protein concentration (c0) are related by the equa-
tion log(t1/2) ¼ a  ((n þ 1)/2)  log(c0), where n is the
initial nucleus size. Even though in this system these vari-
ables show a linear relationship (Fig. 2 A), the calculated
n has a negative value (n ¼ 0.30). This is because the
data set displays a subdependence between log t1/2 and log
c0, a typical feature of fibrillation processes that are affected
by secondary nucleation (33). In these experiments, the
samples were stirred with a magnetic bar, which facilitates
fibril fragmentation. To test this possibility, we incubated
1 mg/ml lysozyme under similar conditions but without stir-
ring. No changes in ThioT fluorescence could be detected,
even after incubation for 50 h (Fig. S6). Even though stirring
may also accelerate the primary nucleation and fibril elon-
gation steps, if only a primary nucleation mechanism is
active, the calculated nucleus size from the log-log plot
should be a positive number. In addition, we cannot rule
out the possibility that the observed subdependence of t1/2
can also be due to a slow unimolecular process, such as
a conformational change that occurs before the onset of
fibrillation. Normalized fluorescence curves were rescaled
following the procedure proposed by Flyvbjerg et al. (34),
where the time axis is replaced by a rescaled time (t/t1/2).
Usually this procedure collapses all curves into a single
one. In the system studied here, the shape of the rescaled
curves clearly depended on protein concentration (Fig. 2 B).
Several kinetic models were fitted to the fibrillation data.
During the fitting procedures, the fibril concentration pre-
dicted by the models was transformed into the expected
ThioT fluorescence signal using the calibration curve shown
in Fig. S5 and compared with the experimental curves.
Models that did not consider secondary nucleation were
successfully fitted to all individual curves, but failed when
we tried a global fit within a broad range of protein concen-
trations. We obtained better agreement when we applied the
analytical solution developed by Knowles et al. (24), which
results from solving the differential equations that describe
a system in which both primary and secondary nucleation
processes are operating. Secondary nucleation can be due
to either lateral nucleation or fibril fragmentation. The
model uses three kinetic constants, which describe primary
nucleation (kn), polymerization (kþ), and secondary nucle-
ation (k). Several nucleus size were tested, and a model
FIGURE 2 Global fitting of fibrillation curves.
(A) Dependence of t1/2 on the initial concentration
of lysozyme (c0). (B) Rescaled curve where t was
replaced by t/t1/2. Only one example of each
concentration is shown. (C) Comparison of the
calculated fibrillation curves using the analytical
solution of a model that considers secondary nucle-
ation (solid lines) and the experimental data
(dotted lines). The curves shown span a range of
lysozyme concentrations from 0.15 to 1.5 mg/ml.
(D) Experimental tlag (black circles) for all exper-
imental curves and calculated tlag (white squares)
of simulated curves for lysozyme concentrations
of 1.5–0.15 mg/ml.
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monomeric nucleus (n ¼ 1) worked properly (fitted param-
eters: kþ  k ¼ 1.5 109 mM1s2, kn/k ¼ 0.059). By us-
ing this model, we could globally fit the curves ranging from
0.15 to 1.5 mg/ml, reproducing their overall shape and lag
times (Fig. 2, C and D). Nevertheless, this model failed
when we attempted a global fit of data acquired over the
complete range of concentrations (0.025–5 mg/ml), suggest-
ing that the underlying fibrillation mechanism could be
even more complicated (Fig. S7). For instance, the fragmen-
tation probabilities could vary along the fibrils and depend
on their length, or changes in the solution viscosity may
affect some of the bimolecular kinetic constants. These
parameters are considered constant by this model, but may
vary as fibril concentration increases along the curves,
which may also depend on the initial total protein concentra-
tion. In addition, an alternative version of this model, which
considers a monomer-dependent secondary nucleation, did
not fit our data.
Global fitting of the model over the complete range of
lysozyme concentrations works adequately for intermediate
protein concentrations, but predicts a faster evolution for
the more concentrated samples and, conversely, a slower
behavior for the more diluted ones (Fig. S7). As we
mentioned above, this model does not consider unimolecu-
lar events that occur before the onset of fibrillation, which
could act as a bottleneck that alters the shape of the curves.
This effect is expected to be more pronounced for the more
concentrated samples, where it might act as the rate-limiting
step. We explored this possibility by studying the unfolding
and refolding kinetics of lysozyme. To this end, we
measured the fluorescence intensity at 354 nm of native orunfolded lysozyme in 7 M Gdn-HCl after dilution to reach
a final concentration of 3 M Gdn-HCl. These measurements
were accomplished by manual mixing, with an estimated
dead time of ~15 s. Single-exponential curves could be
fitted for both experiments, yielding a half lifetime of 55
and 49 s for the unfolding and refolding curves, respectively
(Fig. S8). The fibrillation curves of the more concentrated
samples displayed tlags of ~1000 s and the final plateau
was reached after ~8000 s, meaning that fibrillation was
slower than the major conformational changes of the pro-
tein. Nevertheless, the nature of the initial aggregating
species is unknown and its kinetics of formation may affect
the experimental curves.
To study the evolution of the kinetic constants along the
data set, we fitted each fibrillation curve individually. We
should point out that only two out of three kinetics constants
of the analytical solution can be determined independently,
and for this reason only the expressions kn/k and kþ  k
can be calculated. The last expression displays a marked
decreasing trend as the protein concentration increases,
whereas kn/k displays a more subtle variation (Fig. S9 A).
Even though it is not possible to determine the individual
kinetic constants, it is constructive to follow their behavior
after assuming that one parameter remains constant along
the data set. For instance, if the secondary nucleation k is
set to a unitary value, kþ is equal to kþ k and kn is identical
to kn/k. Under this assumption, the fibrillation constant kþ
shows a marked decreasing trend when the total protein
concentration is increased, displaying a 28-fold varia-
tion between its extreme values. The primary nucleation
constant kn displays a similar behavior but with a smaller
slope, showing a 5-fold variation (Fig. S9 B). Since fibrilBiophysical Journal 107(3) 711–720
FIGURE 3 Effect of inhibitors on lysozyme fibrillation. (A) Lysozyme
fluorescence intensity at 319 nm for increasing concentrations of di-
GlcNAc (squares) and tri-GlcNAc (triangles). The lines represent the fitting
to a model that considers binding and unfolding equilibria. (B) Fibril forma-
tion by 0.5 mg/ml lysozyme followed by ThioT fluorescence with the indi-
cated concentrations of tri-GlcNAc. (C) Fibril formation by 0.3 mg/ml
lysozyme followed by ThioT fluorescence with the indicated concentrations
of di-GlcNAc or tri-GlcNAc.
716 Pagano et al.fragmentation is a unimolecular process, in principle its
kinetic constant k likely will not depend on the medium
viscosity. Conversely, kþ and kn describe bimolecular events
and their values are expected to depend on that feature.
Furthermore, this dependence will be magnified for the
fibrillation constant kþ, since that process involves bigger
species. Therefore, we can speculate that viscosity changes
that occur as the protein concentration increases or along
each fibrillation curve could explain at least in part the
results of the global fitting. Nevertheless, one should bear
in mind that a good fitting of a model only supports a plau-
sible mechanism, and is far from being a definitive proof.
Two effects related to the nonlinear response of the fluo-
rescence signal are worth mentioning. First, the calculated
fibril concentrations obtained using the analytical solution
clearly display a positive slope at time zero (Fig. S10 A).
By contrast, a lag phase with zero slope is evident in the
experimental curves. This difference is due to the detection
limit of the assay, because the fibril concentration must
exceed this limit in order to be detected. This effect is taken
into account in the calibration curve used here, and the
calculated signals are very similar to those measured exper-
imentally (Fig. S10 B). Second, we found that the rescaling
procedure failed to collapse the experimental curves into a
single one (Fig. 2 B). Rescaling of the predicted fibrillation
curves assuming a linear signal response indeed renders a
complete collapse of all curves (Fig. S10 C), which shows
that this kinetic model also follows the rescaling property.
By contrast, an analogous procedure with the calculated
fluorescence signal using the calibration curve (Fig. S10 D)
yielded a result similar to those observed experimentally.
This shows that the lack of collapse is at least in part due
to the nonlinear signal response.
Finally, even though filament fragmentation increases
the complexity of the process, other usual protocols for
fibril formation without stirring involve harder conditions
than those employed here (such as pH 1–2 and 57–70C)
(35,36). Under these conditions, lysozyme suffers an exten-
sive unfolding and therefore the natural inhibitors employed
here bind very poorly to the protein. For instance, the disso-
ciation constant of tri-GlcNAc in 3 M Gdn-HCl at 45C is
0.13 mM (Fig. 3 A), whereas at pH 2 and 70C no significant
binding could be measured even at 2 mM ligand concentra-
tion (Fig. S11). This observation precluded the use of such
conditions for this study. By contrast, 3 M Gdn-HCl lies
in the middle of the unfolding curve at this temperature
(Fig. S1 C), and therefore half of the protein population
remains in the native conformation and inhibitors can bind
at relatively low concentrations.Effect of kinetic inhibitors on the onset time
of lysozyme fibrillation
We studied lysozyme binding to the natural inhibitors di-
GlcNAc and tri-GlcNAc by performing intrinsic fluores-Biophysical Journal 107(3) 711–720cence spectroscopy under the same conditions employed
for fibril formation. In this milieu, lysozyme displays a fluo-
rescence maximum at 346 nm and inhibitor binding exerts
a blue shift of this maximum (lmax ¼ 334 and 333 nm for
Kinetic Inhibition of Fibrillation 717di-GlcNAc and tri-GlcNAc, respectively) (Fig. S12). A
model that takes into account protein denaturation and
ligand-binding equilibria was fitted to the measured fluores-
cence intensity at 319 nm (Fig. 3 A). To this end, we em-
ployed the unfolding constant at 3 M Gdn-HCl derived
from the unfolding experiment (Kunf ¼ 1) (Fig. S1 C).
Ligand dissociation constants in 3 M Gdn-HCl and 45C
span over one order of magnitude (1.9 mM for di-GlcNAc
and 0.13 mM for tri-GlcNAc), representing a DDG0binding
of 7 kJ/mol. In the absence of Gdn-HCl, the dissociation
constants at 45C are lower (0.33 mM for di-GlcNAc
and 30 mM for tri-GlcNAc), in agreement with previous
observations (37). In addition, the dissociation constant
for tri-GlcNAc in the absence of Gdn-HCl and at physiolog-
ical temperature is 16 mM (Fig. 3 A).
We next studied the effect of the inhibitors on fibril for-
mation. In these experiments, protein concentrations varied
between 0.05 and 1.5 mg/ml, and inhibitor concentrations
ranged from 1 to 5 mM for di-GlcNAc and from 0.5 to
2.5 mM for tri-GlcNAc. We acquired a total of 37 curves
using different combinations of protein and inhibitor con-
centrations (see Table S1 for details). The CD spectra along
the fibrillation curve in the presence of tri-GlcNAc (Fig. S2
C) were similar to those measured with the protein alone
(Fig. S2 B), displaying a slower change but reaching a
similar final spectrum (Fig. S2 D). Moreover, fibrils formed
by lysozyme in the presence of inhibitors displayed the
same morphology as those obtained with lysozyme alone,
as revealed by AFM (Fig. 1 B) and TEM (Fig. S3, C and
D). These results indicate that the inhibitors did not alter
the final structure of the fibrils.
The presence of inhibitors induced a delay on tlag and a
reduced slope of the fibrillation curves in a dose-dependent
manner (Fig. 3 B), and these changes were enhanced as the
affinity of the inhibitor increased (Fig. 3 C). Qualitatively
similar results have been obtained in other systems with
different proteins and inhibitors (16,17). To rule out possible
nonspecific contributions of the sugars, we performed
similar experiments in the presence of 10 mM a-methyl-
mannoside. This compound did not bind to lysozyme
(Fig. S13 A) and it did not affect the fibrillation behavior
of the protein (Fig. S13 B).
Since the unfolding and ligand dissociation constants are
known, we were able to calculate the concentration ofunbound species (native and denatured) at the beginning
of the experiments. In addition, from the tlag versus protein
concentration curves in the absence of inhibitors (Fig. 2 D),
we could estimate the expected lag time for any protein con-
centration within this range. This estimation was performed
for the total protein concentration in solution and for the
concentration of unbound species present at equilibrium.
A comparison between the experimental tlag in the presence
of inhibitors and the estimated values using either the total
protein concentration or the concentration of unbound spe-
cies showed that the latter better described the observed
tlag (Fig. S14), although a poor correlation was displayed.
ThioT fluorescence usually increases at earlier times than
tlag calculated by the extrapolation method (Fig. 1 D).
Therefore, calculated tlag obtained by this procedure overes-
timates the time required for the detection of the initial fluo-
rescence increment. This difference is more pronounced for
slow-progressing curves, such as those measured in the pres-
ence of inhibitors. For this reason, we developed a new
method to estimate fibrillation lag times more accurately.
This method is a numeric variational approach in which a
split derivatable function is fitted to the initial segment of
the experimental curves (up to 5% progression). This split
function is composed of a straight line followed by a
quadratic polynomial. The contact time between both func-
tions (t) is used as a parameter to generate a set of test func-
tions, which are individually fitted to the experimental data.
The quadratic error of the fittings for each t presents a
global minimum at a particular time (named tlag). This point
accurately reflects the moment when the experimental
signal first departs from the initial baseline, yielding a
more precise estimation of lag times (Fig. 4 A). In all cases,
tlag is lower than tlag, with the difference being higher for the
slower curves measured in the presence of inhibitors
(Fig. S15). In addition, the stochastic nature of the fibrilla-
tion process is evidenced by the greater dispersion of tlag
values as the total protein concentration employed decreases
(Fig. S16).
The tlag values were calculated for all experimental
curves with and without inhibitors. In the absence of inhi-
bitors, a log-log plot of tlag versus protein concentration
displayed a linear behavior (Fig. 4 B). An empirical function
was fitted to this data, allowing the prediction of tlag for any
protein concentration. We used this function to estimate theFIGURE 4 Analysis of fibrillation using tlag. (A)
Variational calculus of tlag. A split continuous
function composed of a linear function (black
line) followed by a quadratic function (gray line)
was fitted to the initial part of a 0.15 mg/ml lyso-
zyme fibrillation curve. The right axis shows the
quadratic error for all t values tested. tlag is the t
where the error is minimal (arrow). (B) Calculated
tlag for all experimental curves in the absence of
inhibitors.
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the total protein concentration or the concentration of
unbound species. Interestingly, the latter values clearly dis-
played a good correlation with the experimental tlag regard-
less of the inhibitor considered (Fig. 5, A and B). These
results show that in this system, the fibrillation-onset times
are mainly determined by the concentration of unbound pro-
tein species present in the binding equilibrium.
It should be mentioned that the effect of the inhibitors
in shifting the lag times depends not only on the degree of
displacement of the ligand-binding equilibrium but also on
the total protein concentration employed. For instance, if
enough inhibitor is added to bind two-thirds of the total
protein, when the lysozyme concentration is 1.5 mg/ml
the expected shift of lag times will be ~1000 s, whereas
when a lysozyme concentration of 0.15 mg/ml is used, a
shift of ~6000 s will be observed. This is because the lag
times depend nonlinearly on the total protein concentration.
For this reason, a dose-response curve can only be per-FIGURE 5 Comparison of experimental and calculated values of tlag. (A
and B) Observed tlag and the calculated tlag using either the total protein
concentration (white circles) or the concentration of unbound species (black
circles) for fibrillation curves measured in the presence of (A) di-GlcNAc
and (B) tri-GlcNAc. Continuous lines represent a linear regression for
each cluster of data. The dashed line is the identity function.
Biophysical Journal 107(3) 711–720formed for a set of curves employing the same concentration
of total lysozyme. In such cases, one can clearly observe an
increase of tlag when the inhibitor concentration is increased
(Fig. S17).DISCUSSION
Kinetic inhibition is a promising approach to treat protein-
misfolding diseases (7). By targeting the initial steps of
the fibrillation process, this strategy diminishes the concen-
tration of early oligomeric forms, which are postulated to be
the most dangerous species (8–11). The recent approval
of tafamidis to treat the systemic amyloidosis caused by
transthyretin illustrates the potential of this approach (16).
Moreover, alternative strategies involving the disruption of
mature fibrils could increment the concentration of small
oligomeric species, probably leading to unexpected and
dangerous consequences. This observation emphasizes the
need to fully understand the fibrillation process and the
underlying mechanism of toxicity to facilitate the develop-
ment of effective therapies.
Fibrillation from folded proteins usually involves a con-
formational change of the native structure before it is
incorporated into fibrils. For this reason, inhibitor-bound
species are not expected to be found in the core of the fibrils,
although they could affect the fibrillation kinetics. Depend-
ing on the structural change involved in fibril formation
and the nature of the interacting surfaces, inhibitor-bound
species may function as capping elements of growing fibrils
or as alternative nucleation sites. In both scenarios, these spe-
cies will no longer be passive bystanders in the process and
thus will affect fibrillation lag times. For example, unnicked
lysozyme delays the fibrillation of the nicked protein at acidic
pH and high temperature (19). To explore this issue, we per-
formed a quantitative study of the effect of two natural inhi-
bitors on the fibrillation kinetics of hen lysozyme.
Correlations between inhibitor affinities for the target
proteins and their effect on the fibrillation processes have
been observed in other systems (17,18). Small ligand bind-
ing involves a variable amount of unbound protein, which in
turn could lead to fibril formation. Our aim in this work was
to study the time course of a fibrillation process in the pres-
ence of a kinetic inhibitor, focusing our attention on the
onset times of fibril formation. To this end, we first studied
the behavior of chicken lysozyme in Gdn-HCl. Under this
condition, the protein formed amyloid fibrils within hours,
as revealed by ThioT fluorescence, CD spectroscopy,
TEM, and AFM. This process follows a complex mecha-
nism, probably involving secondary nucleation due to fibril
fragmentation. In agreement with these results, an analytical
solution of a model that considers this kind of secondary
nucleation could be fitted to our data within a broad protein
concentration range (24).
The natural inhibitors di-GlcNAC and tri-GlcNAc de-
layed the onset of fibrillation in a dose-dependent manner.
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stronger effect than di-GlcNAc, as would be expected
considering the higher affinity of the former. Using the lyso-
zyme unfolding curve and the measured inhibitor binding
constants, we calculated the concentration of the relevant
species at the beginning of the fibrillation curves. We used
this information to predict the expected tlag considering
the total protein concentration or the concentration of un-
bound protein species. A comparison of the observed tlags
in the presence of inhibitors with the predicted values
showed a better correlation with values calculated using
the concentration of unbound species. Nevertheless, this
correlation was poor and depended on the inhibitor identity.
This is because tlag calculated using the extrapolation
method overestimates the time of the initial fluorescence
signal change, and this effect is more dramatic for slow-
progressing curves such as those obtained in the presence
of inhibitors. For this reason, we developed a method
based on a variational approach. The lag times calculated
through this method (tlag) more accurately reflect the fibril-
lation onset times. Using this approach, we performed an
analysis similar to the one described above. The results
showed that the experimental tlag correlated well with the
tlag calculated using the concentration of unbound species
present in the binding equilibrium. Moreover, this correla-
tion held true for both inhibitors regardless of their affinity
for the target protein. On the other hand, it has been shown
that stabilizing osmolytes such as glycerol or sorbitol can
alter the kinetics of fibril assembly through semispecific
mechanisms (38). These effects require high osmolite con-
centrations, within the molar range. The highest inhibitor
concentration employed here was 5 mM; therefore, it is
not likely that such effects made any important contribution
in this study.
In summary, we found that for the particular system stud-
ied here, the onset times of fibril formation are mainly
dictated by the concentration of unbound protein species
present in the binding equilibrium. In principle, the initial
behavior of this system is insensitive to the presence of
the ligand-protein complex. Most importantly, knowledge
about the aggregation kinetics of the target protein and the
affinity of the inhibitors suffices to predict the onset times
of fibrillation. It remains to be established whether this
conclusion can be extrapolated to other systems. In such
scenarios, effective therapies based on kinetic inhibition
should take into account the long-term effect of unbound
species and control their concentration accordingly to pre-
vent the eventual initiation of deleterious processes.SUPPORTING MATERIAL
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